Table 3.
Fluoroquinolone Exposure in Hospitalized Patients: Subgroup Analysis by Disease State
| Pneumonia (n = 6820) |
Positive Urine Culture (n = 4928) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion Receiving Fluoroquinolone % (95% CI) [n/N] |
Fluoroquinolone Treatment Days per 1000 Patientsa (95% CI) |
Proportion Receiving Fluoroquinolone % (95% CI) [n/N] |
Fluoroquinolone Treatment Days per 1000 Patientsa (95% CI) | |||||||||
| Without Fluoroquinolone Stewardship: 4694 Patients, 34 Hospitals |
With Fluoroquinolone Stewardship: 2126 Patients, 14 Hospitals |
P Value | Without Fluoroquinolone Stewardship: 4559 Patients, 34 Hospitals |
With Fluoroquinolone Stewardship: 2094 Patients, 14 Hospitals |
P Value | Without Fluoroquinolone Stewardship: 3544 Patients, 34 Hospitals |
With Fluoroquinolone Stewardship: 1384 Patients, 14 Hospitals |
P Value | Without Fluoroquinolone Stewardship: 3464 Patients, 34 Hospitals |
With Fluoroquinolone Stewardship: 1378 Patients, 14 Hospitals |
P Value | |
| Any location (inpatient or after discharge) | 55.2% (49.1–61.3%) [2591/4694] |
43.1% (34.9–51.4%) [916/2126] |
.01 | 3540 (3038–4043) | 2456 (1899–3013) | .004 | 45.2% (41.4–49.0%) [1602/3544] |
34.3% (28.0–40.5%) [475/1384] |
.005 | 2902 (2594–3211) | 2252 (1718–2786) | 0.07 |
| Inpatient only | 21.1% (14.0–28.3%) [990/4694] |
9.1% (3.9–14.2%) [193/2126] |
.01 | 426 (309–543) | 181 (85–277) | .01 | 10.8% (8.4–13.2%) [383/3544] |
8.5% (4.8–12.1%) [118/1384] |
.31 | 246 (188–304) | 158 (84–231) | 0.07 |
| Started as inpatient and continued after discharge | 28.0% (23.4–32.6%) [1314/4694] |
13.2% (9.2–17.1%) [281/2126] |
<.001 | 2363 (1909–2816) | 1084 (791–1376) | <.001 | 20.1% (17.4–22.7%) [712/3544] |
9.7% (6.1–13.2%) [134/1384] |
<.001 | 1674 (1430–1919) | 941 (529–1353) | 0.02 |
| After discharge only | 7.8% (5.2–10.3%) [366/4694] |
(16.8% (10.2–23.4%) [357/2126] |
.001 | 532 (376–687) | 1027 (639–1415) | <.001 | 9.7% (7.8–11.7%) [344/3544] |
12.8% (9.9–15.8%) [177/1384] |
.04 | 691 (537–845) | 904 (590–1218) | 0.19 |
All data were adjusted for clustering by hospital and patient characteristics. Fluoroquinolone stewardship includes pre-prescription approval and/or prospective audit and feedback targeting fluoroquinolones.
Abbreviation: CI, confidence interval.
aExcludes patients lacking a documented discharge duration of fluoroquinolone therapy (253/11 748, 2.2%).